USCOM LIMITED — Regulatory Filings 2009

Mar 25, 2009

==> picture [71 x 87] intentionally omitted <==

MARKET ANNOUNCEMENT

USCOM publication in heart transplantation and heart failure

Thursday, 26th March 2009: Uscom (ASX Code: UCM) today announced a new peer reviewed publication in the prestigious U.S. Anesthesia and Analgesia journal demonstrating the potential application of USCOM in heart failure subjects with artificial hearts. The research was conducted as a collaboration between the Departments of Anesthesiology and Surgery at The University of Arizona College of Medicine in Tucson, Arizona and the Department of Medicine at The University of Queensland, in Brisbane, Australia.

The University of Arizona Cardiac Surgical programme is led by the world leading cardiac surgeon Professor Jack Copeland with Professor Peter Lichtenthal as the Director of Cardiovascular Anaesthesia, both co-authors of the current publication.

Uscom CEO, Mr. Paul Butler said “This presentation confirms an emerging application for USCOM in the role of management and monitoring heart failure patients. Optimal management of the circulation of heart failure patients is critical to their survival and depends on reliable and accurate measurements of cardiac performance. This study confirms USCOM’s accuracy and applicability in heart failure.”

Mr Rob Phillips, Executive Chairman and Director of Clinical Science said “This has been a great collaboration. The cardiac surgical programme at Tucson is one of the finest in the world and this study shows USCOM has a role to play in the growing group of patients living with heart failure.”

Reference: Phillips RA, Lichtenthal PR, Sloniger JA, Burstow DJ, West MJ, Copeland JG. Noninvasive Cardiac Output Measurement in Heart Failure Subjects on Circulatory Support. Anesth Analg 2009;108:881-6

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts

Paul Butler Chief Executive Officer Office: +1 646 379 3278 paul.butler@uscom.com.au

Rob Phillips Executive Chairman Office: 02 9247 4144 rob@uscom.com.au

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090